RET and medullary thyroid gland carcinoma: AMG-706 Finally, in a third abstract reported at the 2007 annual meeting of the American Society of Clinical Oncology, AMG-706, another multikinase inhibitor (VEGF/PDGF receptors, Kit and RET), was studied in a phase II trial of patients with advanced differentiated thyroid cancer or medullary thyroid cancer.